Results 211 to 220 of about 74,181 (306)

The role of group III/IV afferent feedback in the ventilatory, pressor and metabolic responses to exercise in normoxia and hypoxia

The Journal of Physiology, EarlyView.
Abstract figure legend Participants completed cycling exercise with (placebo) and without (25 µg intrathecal fentanyl) intact group III/IV muscle afferent feedback in three settings: normoxia, acute hypoxia and chronic hypoxia after 7–9 days of acclimatisation (∼3800 m). Blocking afferent feedback suppressed exercise hyperpnoea across all environments,
Elliott J. Jenkins, Phuong L. Ha, Connor A. Howe, Jay M. J. R. Carr, Justin A. Monteleone, Andrew J. M. Douglas, Abigail Nicholson, Andrew Steele, Brydie Lemkes, Jodie L. Koep, L. Madden Brewster, Jennifer Duffy, Mathew I. B. Debenham, Tena Monaghan, Declan Isaak, Jacob McCormick, Brian H. Dalton, Chris J. McNeil, Jared Baylis, David MacLeod, Mike Stembridge, Markus Amann, Philip N. Ainslie, Travis D. Gibbons   +23 more
wiley   +1 more source

Suspected hyperthyroidism‐associated myoclonus in a cat

Veterinary Record Case Reports, Volume 14, Issue 4, November 2026.
Abstract A 10‐year‐old, male, neutered domestic shorthair cat presented with a 2‐week history of progressively worsening myoclonic jerks predominantly involving the head. Jerks were continuous and marked at rest, but became less intense during activity.
Magdalena Maria Dyrka, Ian Ramsey, Fiona May Keir James, Grace Kadler, Jessica Zilli, Rodrigo Gutierrez Quintana   +5 more
wiley   +1 more source

Admixture Mapping Reveals Candidate Regions for Methotrexate Neurotoxicity Susceptibility: A Reducing Disparities in Acute Leukemia Consortium Report

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
ABSTRACT Background Neurotoxicity is a rare, often dose‐limiting adverse effect of methotrexate (MTX) therapy that disproportionally affects Latino children. Factors contributing to the observed disparity are not well understood. This study leveraged admixture mapping to identify genetic regions associated with MTX‐related neurotoxicity susceptibility ...
Rachel D. Harris, Priya B. Shetty, Olga A. Taylor, Elizabeth G. Atkinson, Melissa A. Richard, M. Monica Gramatges, Mark Zobeck, Sandi Pruitt, Amy Hughes, M. Brooke Bernhardt, Ashley Chavana, Van Huynh, Kathleen Ludwig, Laura Klesse, Kenneth Heym, Timothy Griffin, Rodrigo Erana, Juan Carlos Bernini, Han Chen, Bing Yu, Philip J. Lupo, Karen R. Rabin, Michael E. Scheurer, Austin L. Brown, The REDIAL Consortium   +24 more
wiley   +1 more source

A Swedish Population‐Based Study Found That Muscle Hypertonia in Children With Cerebral Palsy Varied by Age, Subtype, Functional Level, and Muscle Group

Acta Paediatrica, Volume 115, Issue 10, Page 2261-2268, October 2026.
ABSTRACT Aim We examined how lower limb muscle tone was related to age, sex, Gross Motor Function Classification System (GMFCS) level, and the cerebral palsy (CP) subtype in Swedish children with CP. Methods This registry‐based cohort study from 2023 to 2024 used data on all 3 216 children aged 1–15 from the Swedish follow‐up program and national CP ...
Gunnar. Hägglund, Ann. I. Alriksson‐Schmidt   +1 more
wiley   +1 more source

Childhood Acute Lymphoblastic Leukemia Survival in Western Kenya: Reduction in Early Deaths and Treatment Abandonment

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Background An earlier study on children diagnosed with acute lymphoblastic leukemia (ALL) at Moi Teaching and Referral Hospital (MTRH) in Kenya reported a low event‐free survival (EFS), excess treatment abandonment, and high induction mortality.
Gilbert Olbara, George Bogonko, Festus Njuguna, Sandra Langat, Martha Kipngetich, Dennis Njenga, Gertjan Johannes Kaspers, Terry Allen Vik   +7 more
wiley   +1 more source

Tracking Health Related Quality of Life From Diagnosis to Follow‐Up Among Australian Children With Acute Lymphoblastic Leukaemia

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Background Acute lymphoblastic leukaemia (ALL) is one of the most treatable forms of paediatric cancer; however, there is a substantial burden of treatment‐related toxicities (TRTs). In addition, the long‐term changes in children's health‐related quality of life (HRQoL) due to toxic treatments are not well understood.
Clare Ghows, Clarissa E. Schilstra, Karen McCleary, Nancy E. Briggs, Rishi S. Kotecha, Richard De Abreu Lourenco, Shanti Ramachandran, Ruelleyn Cockcroft, Rachel Conyers, Siobhan Cross, Luciano Dalla‐Pozza, Peter Downie, Tamas Revesz, Michael Osborn, Frank Alvaro, Claire E. Wakefield, Glenn M. Marshall, Toby Trahair, Marion K. Mateos, Joanna E. Fardell   +19 more
wiley   +1 more source

International Pain and Spine Intervention Society Emergency Protocols: Intradural or Intrathecal Local Anesthetic Injection. [PDF]

Interv Pain Med
Nagpal AS, Klessinger S, Waring PH, Schneider BJ.   +3 more
europepmc   +1 more source

FGF13 Deficiency Ameliorates Paclitaxel‐Induced Neuropathic Pain by Inhibiting VASH1‐Mediated Microtubule Detyrosination to Promote Mitophagy

Advanced Science, Volume 13, Issue 51, 14 September 2026.
FGF13 is upregulated in DRG neurons of PIPNP model mice. DRG neuron‐specific knockout of FGF13 ameliorates PIPNP symptoms. Mechanistically, FGF13 potentiates microtubule detyrosination by promoting VASH1 binding to microtubules. FGF13 knockout suppresses VASH1‐mediated microtubule detyrosination and promotes α‐tubulin tyrosination.
Yiming Dong, Yidan Wang, Simeng Lv, Zishan Dong, Kaixi Zhi, Xiuhua Guo, Xuyan Li, Ruoxi Yu, Yiyi Zhang, Siyuan Cheng, Chuan Wang   +10 more
wiley   +1 more source

Provider assessment of caregiver reliability in preparation for intrathecal baclofen use in pediatric conditions. [PDF]

J Pediatr Rehabil Med
Thomas SP, Buck J, O'Reilly T, Macdonald C, Ma M, Sawyer KE.   +5 more
europepmc   +1 more source

Rethinking tau‐targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract Tau pathology is more closely associated with cognitive deterioration than amyloid burden in symptomatic Alzheimer's disease (AD), yet tau‐targeted trials have often interpreted decreases in soluble phosphorylated tau (p‐tau) as evidence of therapeutic success. Emerging data argue for a more biology‐informed framework.
Charlotte E. Teunissen, Lorenzo Pini, Bruno P. Imbimbo   +2 more
wiley   +1 more source